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Abstract
Background: The pharmacological treatment of bipolar disorder has dramatically improved with
multiple classes of agents being used as mood-stabilizers, including lithium, anticonvulsants, and
atypical antipsychotics. However, the use of these medications is not without risk, particularly
when a patient with bipolar disorder also has comorbid medical illness. As the physician who likely
has the most contact with patients with bipolar disorder, psychiatrists must have a high index of
suspicion for medical illness, as well as a basic knowledge of the risks associated with the use of
medications in this patient population.
Methods: A review of the literature was conducted and papers addressing this topic were selected
by the authors.
Results and discussion: Common medical comorbidities and treatment-emergent illnesses,
including obesity, diabetes mellitus, dyslipidemia, cardiac disease, hepatic disease, renal disease,
pulmonary disease and cancer are reviewed with respect to concomitant use of mood stabilizers.
Guidance to clinicians regarding effective monitoring and treatment is offered.
Conclusions:  Mood-stabilizing medications are necessary in treating patients with bipolar
disorder and often must be used in the face of medical illness. Their safe use is possible, but requires
increased vigilance in monitoring for treatment-emergent illnesses and effects on comorbid medical
illness.
Background
Patients with bipolar disorder are among the most chal-
lenging to treat pharmacologically, especially in the pres-
ence of medical comorbidity. Although the rates of
medical comorbidity are high in patients with bipolar dis-
order (20–80%), medical illnesses are frequently under-
diagnosed and inadequately treated in psychiatric
patients. For example, Cradock-O'Leary and colleagues
reviewed centralized Veterans Affairs data and examined
the use of medical services by 175,653 veterans during fis-
cal year 2000 [1]. They identified 3,694 veterans with a
primary diagnosis of bipolar disorder and compared the
care that these veterans received to that of all veterans.
Among all veterans with diabetes and hypertension, those
with a comorbid diagnosis of bipolar disorder (as well as
those with diagnoses of anxiety disorder, schizophrenia,
post-traumatic stress disorder, or a substance use disor-
der) were less likely to have more than one medical visit
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in one year. This is especially concerning given that veter-
ans are afforded medical and psychiatric treatment within
one comprehensive health care system, seemingly making
care more accessible. Patients with bipolar disorder in the
general population are likely receiving even less medical
care. The significance of this finding is that the psychiatrist
may be the only physician caring for these patients on a
regular basis. Therefore, psychiatrists must have a high
index of suspicion for medical illness, as well as a basic
knowledge of the risks associated with the use of medica-
tions in this patient population.
The purpose of this paper is to identify common medical
comorbidities in bipolar disorder, including those that are
treatment–emergent, and to offer guidance to clinicians
regarding effective monitoring and treatment.
Material and methods
An extensive review of effective pharmacotherapies is
beyond the scope of this paper which will perform a selec-
tive review the psychotropic medications often prescribed
to patients with bipolar disorder, with an emphasis on
their use in patients with medical comorbidity. More spe-
cifically, the review results include papers concerning
bipolar patients with obesity, diabetes mellitus, dyslipi-
demia, cardiac, hepatic, renal and pulmonary disease and
cancer.
It is essential to keep in mind that benefit cannot be
deleted from the risk:benefit analysis. In some cases a
medication with greater side effects or medical risk may be
the preferred treatment because of the documented effi-
cacy of the agent either in general, or in a particular
patient.
This paper will perform a selective review of the psycho-
tropic medications often prescribed to patients with bipo-
lar disorder, with an emphasis on their use in patients
with medical comorbidity. Currently, lithium, valproate,
olanzapine, lamotrigine, risperidone and quetiapine are
indicated for use in bipolar disorder by the US Food and
Drug Administration (FDA). Aripiprazole has recently
been submitted to the FDA for approval in the treatment
of bipolar disorder. Other agents are also used as adjuncts,
despite limited efficacy data. As such, mention of a medi-
cation in this article does not necessarily imply efficacy,
and the reader is referred to the American Psychiatric




Obesity is a leading cause of preventable death in the
United States, with an estimated 300,000 people dying
annually of obesity-related causes [2]. Although the gen-
eral population in the United States is increasingly more
overweight and obese, 64.5% and 30.5%, respectively, in
a 1999–2000 survey, individuals with bipolar I disorder
are still slightly more likely to be obese [3]. Fagiolini and
colleagues found that 35.4% of patients with bipolar dis-
order were obese. Pharmacotherapy and affective epi-
sodes both influence appetite and physical activity,
thereby increasing the risk for obesity. Obesity in bipolar
patients is correlated with a greater number of lifetime
depressive and manic episodes, a more severe and diffi-
cult-to-treat index episode, and a greater risk of develop-
ing an affective recurrence, most often depression [4].
Persons with bipolar disorder are more likely to be over-
weight (body mass index [BMI] of 25–29.99 kg/m2) or
obese (BMI of 30 kg/m2 or greater) even when mood is
euthymic. Elmslie and colleagues found the prevalence
rates for obesity and being overweight in euthymic female
bipolar patients were 1.5 and 1.8 times greater, respec-
tively, when compared to the reference group [5]. Obesity
was also more prevalent in male euthymic patients com-
pared with the reference group. In both male and female
bipolar patients, truncal obesity was most prominent.
This pattern of obesity reflects fat that is distributed cen-
trally between the thorax and pelvis and is associated with
increased risk of type 2 diabetes mellitus, dyslipidemia,
hypertension, stroke, ischemic heart disease and early
mortality [6-9]. The authors concluded that the preva-
lence of obesity in this study of outpatients was related to
the use of antipsychotics, but less so lithium or anticon-
vulsants. Of those persons prescribed no psychotropics,
less than 10% were obese, suggesting that bipolar disorder
itself does not cause obesity, and that pharmacologic
treatment and gender are greater influences [10].
Important factors influencing obesity in bipolar patients
include nutrient intake and physical activity. In assessing
the nutrient intake of persons with bipolar disorder,
Elmslie and colleagues found that they had increased
intake of carbohydrates and sweets, especially non-alco-
holic sweetened drinks [5]. The intake of sucrose was
higher in patients, particularly females, receiving antipsy-
chotics than in those receiving other or no medications.
Patients with bipolar disorder were also more sedentary,
exercising less frequently and with less intensity than ref-
erence subjects. Medication side effects such as dry mouth
and increased thirst may lead to increased consumption
of sweetened drinks. Sedation, decreased motivation and
impaired coordination may promote physical inactivity.
Obesity in patients with bipolar disorder should not be
the only factor used to inform selection of psychotropics.
In fact, patients who are obese at baseline may be less
likely to have significant weight gain than those with a
lower baseline body mass index. At the same time,Annals of General Hospital Psychiatry 2004, 3 http://www.general-hospital-psychiatry.com/content/3/1/7
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though, use of certain psychotropic medications may
make it more difficult for those patients to lose weight.
Patients should be weighed at baseline and again two
weeks after beginning treatment. If the patient gains four
pounds or more, behavioral interventions of diet and
exercise and a consultation with a nutritionist should be
considered. Specific dietary modifications should include
avoidance of refined carbohydrates, including sweetened
drinks, increased intake of omega-3 fatty acid, and small
amounts of protein with each meal [11]. Behavioral inter-
ventions can lead to significant loss of weight gained
while taking atypical antipsychotics, and the modifica-
tions of eating and exercise habits help patients maintain
the weight loss [12].
Pharmacologic treatment of obesity should be avoided if
at all possible, given the risk of side effects and drug inter-
actions. Pharmacologic agents should be reserved for
those patients with a BMI of 30 kg/m2 or greater, or a BMI
of 27 kg/m2 or greater and risk factors for weight related
medical illnesses [12]. Agents associated with weight loss
include metformin [13-15], topiramate [16], sibutramine
[12], amantadine [18,19], nizatidine [19] and orlistat
[20]. Centrally acting agents have a theoretical risk of
exacerbating psychosis or mood disorders and should be
used with caution [22,23].
Gastric restrictive surgical interventions may be consid-
ered for patients whose BMI exceeds 40 kg/m2 and who
have not responded to behavioral interventions or phar-
macologic treatment [12].
Diabetes mellitus
Cassidy and colleagues reported the prevalence of diabe-
tes mellitus in hospitalized bipolar patients to be approx-
imately three times the national average [24]. Further,
bipolar patients with diabetes mellitus had more lifetime
psychiatric hospitalizations than non-diabetic bipolar
patients. It is prudent, therefore, for psychiatrists to be
aware of the risk factors associated with diabetes, includ-
ing treatment-emergent diabetes. Recent publications
linking atypical antipsychotics with treatment-emergent
diabetes are numerous, but often contradictory. There are
reports of hyperglycemia associated with risperidone,
quetiapine and ziprasidone, and more frequently with
clozapine and olanzapine [26,27].
Of note, those with baseline risk factors for diabetes mel-
litus are more likely to develop treatment-emergent diabe-
tes (TED). Sowell identified risk factors for patients who
entered clinical trials and later developed TED [28]. At
study entry these patients had higher random glucose lev-
els, were older, more obese and more likely to possess
multiple risk factors for DM. Neither treatment-emergent
weight gain nor treatment group significantly impacted
the risk for TED. Established risk factors for diabetes
include: family history, ethnicity, increasing age, central
obesity, physical inactivity, low HDL/high triglycerides,
fasting glucose of 110 mg/dL or greater, gestational diabe-
tes, hypertension, and polycystic ovary syndrome.
Though questions remain about the pathophysiology of
treatment-emergent diabetes, guidelines are being formu-
lated to aid clinicians in identifying patients at risk.
Screening for diabetes should include questioning
patients about symptoms such as excessive thirst and uri-
nation, nocturia, unexplained weight loss, fatigue, fre-
quent infections, and blurred vision. Recommendations
for fasting glucose screening at baseline and follow-up for
patients receiving atypical antipsychotics are presented in
Table 1[29].
Dyslipidemia
The effects of atypical antipsychotics on lipid levels have
been reported primarily in patients with schizophrenia.
Studies of patients on atypical antipsychotics, as well as
high potency neuroleptics, show a significant association
between weight gain and cholesterol and triglyceride ele-
vation in patients with schizophrenia. This association is
most commonly observed in patients prescribed clozap-
ine and olanzapine, reaching statistical, though not neces-
sarily clinical significance [26,30-33]. Olanzapine,
risperidone and quetiapine have also been shown to
decrease mean low-density lipoprotein (LDL) levels, and
olanzapine may also lower mean high-density lipoprotein
(HDL) levels [30]. Some studies indicate that ziprasidone
may lower cholesterol and serum triglycerides [27]. As
such, some authors recommend monitoring body weight,
fasting cholesterol and triglycerides at baseline and every
six months in routine clinical practice with all antipsy-
chotics [26].
Table 1: Diabetes Mellitus Screening Recommendations For Patients Treated with Atypical Antipsychotics [29]
Initiation of Treatment • Baseline fasting glucose level
First Year of Treatment • Fasting glucose level every 3–4 months
• Observe for signs of hyperglycemia
Duration of Treatment • Fasting glucose level every 6 months in high-risk patients
• Fasting glucose level every 12 months in patients with normal glucose 
levels during first year of therapyAnnals of General Hospital Psychiatry 2004, 3 http://www.general-hospital-psychiatry.com/content/3/1/7
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The effects of anticonvulsants on serum lipid and choles-
terol levels have been studied primarily in patients with
seizure disorders. Carbamazepine-induced increase in
total cholesterol is primarily due to an increase in HDL
[34]. This occurs during the initial weeks of therapy, per-
sists throughout treatment and reverses in the first few
weeks after discontinuation. A 5-year prospective study of
patients treated with carbamazepine also revealed a tran-
sient increase in LDL cholesterol and triglycerides in the
first year of treatment [35]. When carbamazepine was
replaced with oxcarbazepine in patients with seizure dis-
orders, total serum cholesterol levels decreased, but HDL
cholesterol and triglyceride levels remained unchanged
[36].
Women with obesity and polycystic ovaries or hyperan-
drogenism treated with valproate have also been shown to
have elevations in serum triglycerides and low HDL to
total cholesterol ratios [37,38]. This is consistent with
insulin resistance in this population. Valproate does not
appear to contribute to clinically significant dyslipidemia
across other populations [38,39]. The effects of lamotrig-
ine and topiramate on serum cholesterol and triglyceride
levels have been reported in small studies and case reports
[16,38]. Neither of these anticonvulsants appears to affect
lipid levels.
Currently there are no published recommendations for
monitoring serum lipids in patients receiving anticonvul-
sants. In patients identified as having polycystic ovaries or
hyperandrogenism, monitoring of lipid levels is
warranted.
Cardiac disease
As discussed above, patients with bipolar disorder have a
higher prevalence of cardiac risk factors, such as obesity,
glucose dysregulation and dyslipidemia. It is not surpris-
ing, therefore, that patients with bipolar disorder also
have greater mortality from cardiovascular disease com-
pared with the general population [40]. Further, many of
the medications that treat bipolar disorder may have car-
diac side effects or toxicity. Underlying cardiac disease
may also affect the pharmacokinetics of psychotropics.
Congestive heart failure (CHF) can affect pharmacokinet-
ics in various ways. Diminished cardiac output results in a
shift of blood flow to vital organs. This may lead to
decreased perfusion of the gastrointestinal tract and skel-
etal muscle with resultant erratic absorption of oral and
intramuscular medications, increased drug delivery to
brain tissue, reduced blood flow to kidneys with resultant
slowed clearance and prolonged elimination half-lives.
Though studies supporting dosing guidelines for psycho-
tropics in CHF are lacking, it has been recommended that
medication doses be reduced by 50% in patients with
CHF [41].
Lithium has been shown to both induce and ameliorate
CHF. In therapeutic doses, lithium probably does not
decrease cardiac contractility. However, if CHF symptoms
worsen, lithium should be discontinued [42]. Patients
with CHF are also at increased risk for orthostatic hypo-
tension, specifically with medications that antagonize
alpha-1 receptors [43]. Medications with significant
alpha-1 blockade include low-potency neuroleptics and
atypical antipsychotics (quetiapine > risperidone > olan-
zapine/ziprasidone). Lithium and anticonvulsants are not
alpha-1 antagonists [44].
Patients with preexisting intraventricular conduction
delays are at increased risk for complete heart block when
given medications with quinidine-like properties, includ-
ing carbamazepine and tricyclic antidepressants [45]. Val-
proate has no known adverse cardiac effects [46]. Lithium
is associated with sinus node dysfunction, which is usu-
ally reversible with discontinuation of medication [42].
There is sparse evidence for first-degree atrial-ventricular
(AV) block and rare reports of aggravation of ventricular
arrhythmias with lithium at therapeutic levels. However,
lithium toxicity may be associated with sinoatrial block,
AV block, AV dissociation, bradyarrhythmias, ventricular
tachycardia, and ventricular fibrillation. T-wave flattening
or inversion with therapeutic lithium levels are of uncer-
tain clinical significance and are usually reversible upon
discontinuation of lithium therapy [42].
Prolongation of the QTc interval on electrocardiograph
(ECG) in the context of antipsychotic medication use has
received increased attention in recent years. Prolongation
of the QT interval greater than 500 ms increases the risk of
torsade de pointes, a polymorphic ventricular tachycardia
that is associated with syncope and sudden death. Several
antipsychotics have been documented to cause torsade de
pointes and sudden death, including pimozide, sertin-
dole, droperidol, haloperidol, and thioridazine, which
has the greatest risk [47]. Risperidone-induced QT prolon-
gation has been observed, including one fatality, though
torsade de pointes was not reported [48]. Ziprasidone has
also been associated with prolongation of the QT interval;
however, to date, no cases of ziprasidone-associated tor-
sade de pointes or sudden death have been reported in the
literature or to the Federal Drug Administration. It should
be pointed out, though, that most of the safety data on
ziprasidone to date originates from clinical trials, with
selective entry criteria likely to exclude patients who are
susceptible to torsade de pointes and sudden death.
A study of the effects of six antipsychotics on the QT inter-
val found that thioridazine produced the most prolonga-Annals of General Hospital Psychiatry 2004, 3 http://www.general-hospital-psychiatry.com/content/3/1/7
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tion (mean change of 35.6 ms), followed by ziprasidone
(20.3 ms), quetiapine (14.5 ms), risperidone (11.6 ms),
olanzapine (6.8 ms), and haloperidol (4.7 ms)
[47,49,50]. These findings are difficult to interpret given
that quetiapine and olanzapine have not been implicated
in cases of torsade de pointes or sudden death, but pro-
duced greater prolongation than haloperidol, which has
been associated with the fatal arrhythmia.
At this time, routine ECG screening and monitoring has
not been recommended before initiating treatment with
antipsychotics. However, a careful medical history should
be taken for symptoms of cardiac pathology, such as
recurrent syncope. A family history of early sudden death
should be obtained and serum electrolyte imbalances
should also be corrected as these may predispose patients
to arrhythmias. It has been suggested that ECG monitor-
ing be undertaken in patients at higher risk, including
those with cardiovascular disease, a history of QT prolon-
gation, polypharmacy (metabolic inhibitors or other
drugs known to affect the QT interval), high doses of
antipsychotics, or symptoms possibly related to arrhyth-
mias (syncope, palpitations, dizziness, etc.). The QTc
interval may not reliably predict the risk for arrhythmia;
however, an examination of the ECG by a cardiologist for
other signs of arrhythmia may facilitate a more useful
assessment of risk [50].
Patients with recent myocardial infarction (MI) are at
increased risk for arrhythmias, heart failure and sudden
death and are frequently treated with numerous medica-
tions, thereby increasing the likelihood for drug interac-
tions with psychotropic medications. Lithium may be
used after MI, but care must be taken to monitor for and
correct any electrolyte aberrations. Of note, lithium in
combination with angiotensin converting enzyme (ACE)
inhibitors may produce an increased risk of arrhythmia
[42,51]. Valproate has an increased risk of liver injury in
conjunction with lipid-lowering agents, as well as risk of
bleeding complications when taken with antiplatelet
agents, warfarin or niacin. Carbamazepine acts as an
inducer of cytochrome 3A4, which may increase the
metabolism of some anticoagulant and cardiovascular
medications. Olanzapine may induce or worsen cardiac
risk factors such as obesity, metabolic derangements and
hyperlipidemia. Quetiapine and risperidone may also
contribute to obesity. Ziprasidone should be avoided due
to increased risk of arrhythmia [51]. Cardiovascular cond-
siderations in the treatment of bipolar disorder are
reviewed in Table 2.
Hepatic disease
Patients with pre-existing liver disease are at increased risk
for liver toxicity due to psychotropic medications. Hepatic
insufficiency increases blood levels and half-lives of all
psychotropic medications, except lithium. Possible mech-
anisms include: decreased oxidative metabolism through
cytochrome enzymes; possible reduction of conjugation
pathways for medications that predominantly undergo
glucuronidation; decrease in hepatic blood flow because
Table 2: Cardiovascular Considerations in the Treatment of Bipolar Disorder
Drug + EKG or Conduction Changes Congestive Heart Failure Orthostatic Hypotension Post-Myocardial Infarction
Lithium * (therapeutic level)  Sinus node dysfunction; T wave 
flattening/inversion; rare 1st degree AV 
block & aggravation of ventricular 
arrhythmias 
May exacerbate symptoms of 
CHF; monitor level due to 
fluid/electrolyte changes
None Monitor for electrolyte aberrations; in 
combination with ACE inhibitors, 
increased risk of arrhythmia
(toxicity) Sinoatrial block; AV block/dissociation 
bradyarrhythmias; ventricular 
tachycardia/fibrillation
Valproate * Unlikely May require decrease in 
valproate dose
None Risk of liver injury in conjunction with 
lipid-lowering agents; risk of bleeding 
complications in conjunction with 
antiplatelet agents, warfarin, niacin
Carbamazepine Quinidine-like properties increase risk 
of complete heart block
May require decrease in 
carbamazepine dose
None Induction of CYP3A4 increases 
metabolism of some anticoagulant & 
cardiovascular drugs
Olanzapine * Unlikely May require decrease in 
olanzapine dose
Minimal Increased cardiac risk factors: weight 
gain, metabolic changes and 
hyperlipidemia
Ziprasidone QT prolongation; risk of torsade de 
pointes
May require decrease in 
ziprasidone dose
Minimal Should be avoided due to increased 
risk of arrhythmia




Increased cardiac risk factors: some 
weight gain




Increased cardiac risk factors: weight 
gain
EKG = Electrocardiogram AV = Atrial-Ventricular CHF = Congestive Heart Failure ACE = Angiotensin Converting Enzyme CYP = Cytochrome 
P450 + Not all agents are appropriate for monotherapy. Inclusion in this table does not necessarily imply efficacy. * Currently FDA approved for use 
in Bipolar Disorder.Annals of General Hospital Psychiatry 2004, 3 http://www.general-hospital-psychiatry.com/content/3/1/7
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of portacaval shunting, thereby decreasing first pass
metabolism; decrease in quantities and affinity of plasma
proteins, thereby increasing free-drug levels; increase in
volume of distribution in patients with ascites [52].
Hepatitis C virus (HCV) infection is a leading cause of cir-
rhosis and liver transplantation in the United States, with
an estimated prevalence of 3 million Americans [53].
There is a high comorbidity between hepatitis C and psy-
chiatric illness. Computerized chart reviews of HCV-
infected veterans revealed that 86.4% had at least one past
or present psychiatric, drug or alcohol-abuse disorder, and
31% had active disorders as defined by recent hospitaliza-
tions to psychiatric or drug-detoxification units [54].
Given the high comorbidity of HCV and psychiatric ill-
ness, we must use caution in prescribing psychotropics
with known hepatotoxicity, especially anticonvulsants.
However, these medications are not necessarily
contraindicated.
Some authors have reported that alanine aminotrans-
ferase (ALT) elevation was not significantly greater when
starting treatment with valproate as compared to antide-
pressants, lithium or gabapentin in patients with HCV
[55]. These findings suggest that valproate can be used for
some patients with HCV without adversely affecting ALT
levels. Obtaining pretreatment baseline ALT levels in
patients with HCV is recommended as well as monitoring
of levels during treatment. Discontinuation of valproate
when aminotransferase levels are "clearly increased above
the normal pretreatment baseline" is recommended [55].
Many patients (10–40%) receiving valproate will experi-
ence a reversible increase in aminotransferases. Valproate-
induced liver injury occurs with a frequency of approxi-
mately 1 per 37,000 persons exposed [56]. Certain groups
have an increased risk of 1 per 500, including those with
personal or family history of mitochondrial enzyme defi-
ciency, Reye's syndrome, Friedreich's ataxia, a sibling
affected by valproate hepatotoxicity, or multiple drug
therapy, as well as children younger than 3 years of age
[57].
Several anticonvulsants have been associated with anti-
convulsant hypersensitivity syndrome (reactive metabo-
lite syndrome), including carbamazepine, phenytoin,
phenobarbital, and lamotrigine. The triad of hypersensi-
tivity includes fever, rash and internal organ involvement
with onset of symptoms within 1 to 8 weeks of exposure.
The frequency of the syndrome is estimated at 10–100 per
100,000 persons exposed. Risk of serious hypersensitivity
reactions among first-degree relatives of those who have
had a reaction to one of these anticonvulsants is about 1
in 4 [57-59].
There are case reports of hepatic injury associated with
other drugs that are commonly used in bipolar disorder.
There have been a few case reports linking olanzapine
with acute hepatocellular injury and one of acute hepatitis
accompanied by hallmarks of a hypersensitivity syn-
drome [57]. Risperidone may cause transient increases in
aminotransferases as well as cholestatic hepatitis [57], but
hepatic disease does not appear to modify drug pharma-
cokinetics [60]. Topiramate has been associated with one
case report of acute hepatic failure in a woman who was
also treated with carbamazepine, as well as one case of
reversible ALT elevation [57].
Recognizing early symptoms of hepatic toxicity and dis-
continuing treatment are important in optimizing recov-
ery. Early symptoms of hepatic toxicity include apathy,
malaise, fever, diminished appetite, nausea, and vomiting
[63]. Regular monitoring of aminotransferases may also
Table 3: Recommended Dosage Adjustments for Patients with Comorbid Hepatic and Renal Disease
Drug + Hepatic Disease Renal Disease
Lithium * May need to increase dose with ascites due to fluid shifts Contraindicated in Acute Renal Failure. HD dosing: 300–600 mg 
in singe post-HD dose
Valproate * Reduce dose with elevated transaminases None
Carbamazepine Reduce dose with elevated transaminases Reduce dose with symptoms of toxicity due to reduced clearance 
of toxic metabolite
Olanzapine * None None
Risperidone * May need to reduce dose Reduce dose by 50–60% due to diminished clearance
Quetiapine * May need to reduce dose None
Ziprasidone None Use intramuscular formulation with caution
Lamotrigine * May need to reduce dose due to prolonged half-life May need to reduce dose
Gabapentin None Dose reduction proportional to rise in creatinine
Topiramate May need to reduce dose as clearance of drug may be 
decreased
Reduce dose by half
HD = hemodialysis + Not all agents are appropriate for monotherapy. Inclusion in this table does not necessarily imply efficacy. * Currently FDA 
approved for use in Bipolar Disorder.Annals of General Hospital Psychiatry 2004, 3 http://www.general-hospital-psychiatry.com/content/3/1/7
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help identify patients with "silent" hepatotoxicity. Refer-
ral to an internist or hepatologist, following discontinua-
tion of the offending agent, is warranted if treatment-
induced liver injury is suspected. If symptoms of anticon-
vulsant hypersensitivity syndrome are apparent, the
patient should be referred for emergency treatment. Dos-
age adjustments for patients with hepatic disease are
shown in Table 3.
Renal disease
The prevalence of chronic kidney disease in the adult pop-
ulation of the United States is 11% (19.2 million people)
[64], and as death rates from heart disease, cancer and
pneumonia decrease, deaths from renal disease are on the
rise [65]. As more of our patients develop renal disease,
psychiatrists must be aware of the effects of psychotropics
on the kidneys, as well the effects of decreased renal func-
tioning on the pharmacokinetics of medications
prescribed.
Of all the medications used to treat bipolar illness, lith-
ium has the greatest effect on the kidney. Lithium is asso-
ciated with an impaired urinary concentrating capacity
resulting in polyuria that can, rarely, become permanent
due to irreversible structural tubular damage [42,66].
Glomerular function is less affected by lithium. Nephrotic
syndrome occurs rarely at therapeutic lithium levels. If
this does occur, lithium discontinuation alone or in com-
bination with diuretics, hemodialysis, or steroids gener-
ally results in improvement [67]. Renal tubular acidosis
(RTA) has also been associated with lithium use and is
more likely in patients with other conditions (medullary
sponge kidney, carbonic anhydrase B deficiency, tubu-
lointerstitial nephropathy), medications producing acido-
sis (amphotericin B, non-steroidal anti-inflammatory
drugs [NSAIDs]), or urinary acidification defects [42].
Patients with preexisting kidney disease are at increased
risk for lithium toxicity and possibly the nephrotoxic
effects of lithium. Lithium is contraindicated in acute
renal failure, though chronic renal failure is not an abso-
lute contraindication with close monitoring. It has been
recommended to maintain lithium levels between 0.6 and
0.8 mEq/L in this setting [42]. Lithium may be used in
patients on hemodialysis (HD) and should be adminis-
tered in a single post-dialysis dose of 300–600 mg. Lith-
ium levels should be checked pre-dialysis and 2–3 hrs
following the post-dialysis dose. There is a case report in
which lithium levels were maintained in the therapeutic
range by intraperitoneal administration of lithium during
continuous peritoneal dialysis [68].
Lithium has been used safely in post-renal transplant
patients. Living-related-donor allograft recipients show
near normal renal function within hours after transplant
and lithium dose may be increased by the first post-trans-
plant day. Cadaveric allograft recipients frequently
develop acute tubular necrosis (ATN) with fluctuating
renal function causing inconsistent serum levels and
increased risk of toxicity [69]. Antirejection drugs also
affect lithium levels: methylprednisolone decreases tubu-
lar reabsorption of lithium and cyclosporine decreases
excretion of lithium [42].
Pharmacokinetics of some medications are altered by
nephrotic syndrome due to low levels of serum albumin
and higher levels of unexcreted metabolites competing for
protein binding sites, resulting in increased bioavailabil-
ity of free, active highly protein-bound drugs. Accumula-
tion of active hydroxylated metabolites of carbamazepine
may lead to symptoms of drug toxicity despite therapeutic
drug levels [70].
Renal insufficiency and failure result in decreased drug
clearance for many psychotropics. Valproate clearance is
diminished by 27% in renal failure; however, it is cleared
by hemodialysis (HD) so no dose adjustment is recom-
mended [71]. The elimination half-life of lamotrigine is
prolonged in renal failure, and dosing may need to be
modified based on the creatinine clearance [72,73].
Gabapentin clearance is linearly related to creatinine
clearance and dose should be decreased accordingly [74].
Topiramate clearance is decreased and the elimination
half-life is prolonged with renal impairment. It is recom-
mended that half the usual adult dose be used in renally
impaired patients. Further, topiramate is a weak carbonic
anhydrase inhibitor and is associated with the develop-
ment of renal calculi. In clinical trials, 1.5% of patients
treated developed renal stones. This risk can be reduced
with adequate hydration [75]. Risperidone clearance is
decreased by 60% and half-life increased in moderate to
severe renal disease, though it is cleared by HD. Dosage
adjustment is recommended in renal disease [60]. The
pharmacokinetics of olanzapine, quetiapine, and oral
ziprasidone are not altered in renal disease [76,77].
Though the intramuscular formulation of ziprasidone has
not been studied in patients with renal impairment,
because the cyclodextrin excipient is renally cleared it is
suggested that it be administered with caution to patients
with renal impairment [78]. Suggested dosage adjust-
ments for medications used in the context of renal disease
are shown in Table 3.
Pulmonary disease
There are few reports of mood stabilizers and atypical
antipsychotics contributing to respiratory depression or
pulmonary disease. One case report of olanzapine-associ-
ated respiratory failure occurred in an elderly patient with
chronic lung disease and the authors recommend careful
observation of patients with chronic lung disease treatedAnnals of General Hospital Psychiatry 2004, 3 http://www.general-hospital-psychiatry.com/content/3/1/7
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with olanzapine [79]. In the clinical trials of quetiapine,
hyperventilation was reported to occur in <1/1000
patients treated and case reports have appeared in the lit-
erature [80]. Lithium, anticonvulsants, risperidone and
ziprasidone do not appear to alter respiratory drive.
Cancer
Patients with cancer are particularly susceptible to the
hematologic and cognitive effects of medications, due to
both their illness and chemotherapeutic treatment. Lith-
ium should be closely monitored as fluid and electrolyte
intake may vary in patients with cancer. Close monitoring
is also necessary when lithium is combined with nephro-
toxic chemotherapeutic agents such as cisplatin. An
increased risk of cognitive dysfunction with lithium, espe-
cially in patients with primary brain tumors or metastasis
has been reported. Carbamazepine has a risk of marrow
suppression, which may produce an additive effect when
combined with chemotherapeutic agents that suppress
blood marrow production. Valproate, risperidone and
olanzapine have been safely used in patients with cancer
[81]. Olanzapine has been studied in patients with cancer
and has been found to have an antiemetic effect [82], as
well as reducing pain scores and opioid requirements in
patients with uncontrolled cancer pain associated with
cognitive impairment or anxiety [83].
Conclusions
The treatment of bipolar disorder is complicated in
patients with medical comorbidity. Patients with
psychiatric illness may not have routine general medical
care and diagnosis of general medical conditions may be
delayed. As the physician with the most (and often the
only) contact with these patients, psychiatrists need to be
vigilant in detecting early signs and symptoms of medical
illness and facilitating referral for appropriate evaluation
and intervention. Psychiatrists must also be aware of the
medical risks of psychotropic medications and their use in
the medically ill population. This paper has reviewed
some of the medications commonly used in bipolar disor-
der and discussed their use with comorbid medical illness.
Drug names
Amantadine (Symmetrel), amphotericin B (Amphocin
and Fungizone), aripiprazole (Abilify), carbamazepine
(Tegretal and others), clozapine (Clozaril), droperidol
(Inapsine and others), gabapentin (Neurontin), haloperi-
dol (Haldol and others), lamotrigine (Lamictal), lithium
(Eskalith and others), metformin (Glucophage), nizati-
dine (Axid), NSAIDs (Ibuprofen, Naproxen and others),
olanzapine (Zyprexa), orlistat (Xenical), oxcarbazepine
(Trileptal), phenytoin (Dilantin and others), pimozide
(Orap), quetiapine (Seroquel), risperidone (Risperdal),
sibutramine (Meridia), thioridazine (Mellaril and others),
topiramate (Topamax), valproate (Depakote), ziprasi-
done (Geodon).
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